2025.01.09
On December 16, 2024, Nona Biosciences (Suzhou) Co., Ltd. ("Nona Biosciences"), a wholly-owned subsidiary of HBM Holdings Limited (stock code: 02142.HK), announced a research collaboration and license agreement to discover next-generation T-cell engagers (“TCEs”) with Candid m88 bonusrapeutics, Inc. ("Candid").
Under m88 bonus terms of m88 bonus agreement, Nona Biosciences is eligible to receive up to USD 320 million, including an upfront payment and potential milestone payments. Candid will be responsible for all furm88 bonusr product development.
m88 bonus was engaged by Nona Biosciences to review and revise the agreement. With its consistent delivery of efficient and rigorous legal services and detail-oriented and professional expertise, m88 bonus’s team was recognized and trusted by the client.
Partnerm88 sport bettingled the m88 bonus team.
